01 August 2022
Consilium Strategic Communications advises Replay on successful $55 million seed financing round led by KKR and OMX Ventures
London, 1 August 2022; Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is proud to have supported Replay on its recently announced $55 million seed financing and launch.
The seed was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial.
Replay’s portfolio of next-generation genomic medicine technologies aims to solve the key challenges currently limiting clinical progress, including the need for increased payload capacity and off-the-shelf cell therapies that substantially reduce cost of goods, improve production speed, volume and consistency, and expand the potential for genome engineering.
The Company’s technologies, which include a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform, aim to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realising its full potential.
“This seed round is a huge validation of Replay’s ambition, its technologies and its extraordinarily deep scientific bench,” said Amber Fennell, Partner at Consilium Strategic Communications. “Working with the team at Replay, we quickly gained an understanding of the Company’s unique approach and structure. We then worked to execute our communications strategy, placing the story with the most respected media outlets, including the Financial Times, WSJ Pro Venture Capital, The Times, Fierce Biotech and Endpoints, among others, and delivering communications collateral to support the launch. We wish the Replay team all the best with the next stage of their growth.”
“We’re really delighted with the support that we’ve received at every step of this critical communication,” said Adrian Woolfson, Executive Chairman and Co-founder of Replay. “Our story is a specialist one and it takes a team with deep understanding of the industry dynamics and the broader perception to convey our ambition and expertise with clarity. Consilium absolutely delivered on this.”
The Consilium team representing Replay on the launch and seed round was Amber Fennell, Tracy Cheung, Andrew Stern, Melissa Gardiner and Genevieve Wilson.
To view Replay’s news announcement, please visit https://www.replay.bio/
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in both Europe and US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to
discrete specialist reputation management projects. For more information please see www.consilium-comms.com.
Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realising its full potential. The Company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies, which leverage the technology platforms. For example, Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company engaging its evolutionary inference machine learning and genome writing technology to optimize functionality. Replay is led by a world-class team of academics, entrepreneurs and industry experts.
The Company has raised $55 million in seed financing and is supported by an international syndicate of investors that includes KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners.